Remove Government Remove Networking Remove Pharmaceutical manufacturing
article thumbnail

Key developments in pharmaceutical manufacturing – September 2023

European Pharmaceutical Review

September 2023 saw a wave of new pharmaceutical manufacturing facility expansions and launches across Europe. Research by the Confederation of British Industry (CBI) , released in September this year, highlighted progress for UK manufacturing in its latest Industrial Trends Survey. Meath opened last month.

article thumbnail

Eli Lilly promises additional $1.6b manufacturing investment

European Pharmaceutical Review

billion and another 200 new jobs is planned for Eli Lilly and Company’s two new pharmaceutical manufacturing sites in Boone County, US. Eli Lilly’s investment here is the largest manufacturing investment at a single location in its history. Students will also be able to access a smart manufacturing lab.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Call to arms as UK falls back in medicines manufacturing

pharmaphorum

Drastic steps need to be taken if the UK is to reverse a steep decline in medicines manufacturing in recent years, according to a cross-industry coalition. ” Image from the Association of the British Pharmaceutical Industry (ABPI).

article thumbnail

Guaranteeing resilience in vaccine manufacturing

European Pharmaceutical Review

There has been a steady stream of developments in the vaccine manufacturing space throughout 2023. A notable milestone was Moderna’s announcement in April that it had, following finalisation of a ten-year strategic partnership with the UK Government, commenced construction of its mRNA vaccine manufacturing technology centre.

article thumbnail

Strengthening and transforming the pharmaceutical supply chain

European Pharmaceutical Review

In this Q&A EPR speaks to Naser Al Yammahi the Deputy CEO of Hayat Biotech about pharmaceutical supply chain challenges and how they can be addressed. Yammahi was instrumental in building Hayat’s extensive distribution network needed to supply vaccines during the COVID-19 pandemic.

article thumbnail

Diversity and inclusion in oncology clinical trials

Clarify Health

Not Enrolled Given this historical backdrop, the FDA and leading biotech and pharmaceutical manufacturers have taken initiatives to ensure: representative clinical trial recruitment that reflects the broader US patient population and equitable access to therapies and vaccines. J National Comprehensive Cancer Network.

article thumbnail

The Pandemic Treaty and the opportunity to end ‘vaccine apartheid’

pharmaphorum

Compounding the situation to understand how such an outcome was allowed to occur is the fact that many deals between government and pharmaceutical companies selling the treatments and vaccines were agreed under terms of confidentiality.